
ARQL
Healthcare · Biotechnology · $2.42B market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2019
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Mar 7, 2019 | Time not confirmed | -0.07 | -0.08 | -14.3% |
| Oct 31, 2018 | Time not confirmed | -0.06 | -0.05 | +16.7% |
| Aug 1, 2018 | Time not confirmed | 0.03 | 0.05 | +66.7% |
| May 7, 2018 | Time not confirmed | -0.06 | -0.07 | -16.7% |
| Mar 5, 2018 | Time not confirmed | -0.09 | -0.09 | 0.0% |
ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company's pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase I trial for patients with B-cell malignancies refractory to other therapeutic options; and…